Peak-sales potential depends on the various indications for which Entinostat is eventually approved—as well as the geographies in which it gains regulatory approval.
I don't have a specific peak-sales forecast for Entinostat; however, NKTR's enormous market-cap rise based on the early clinical data for NKTR-214 shows how valuable a drug to make "cold" tumors "hot" could potentially be.
News 
Market Data 
Discover 
